| Tomillero A, Moral MA
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 May; 31(4):263-98.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Tomillero A, Moral MA
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 Apr; 31(3):183-227.
Abstract | Full Citation |
| Molina JM, Ait-Khaled M, Rinaldi R, et al.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. [JOURNAL ARTICLE]
J Antimicrob Chemother 2009 Jun 10.
Abstract | Full Citation |
| Pulido , Estrada , Baril , et al.
Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks. [Journal Article]
HIV Clin Trials 2009 Mar-Apr; 10(2):76-87.
Abstract | Full Citation | Find Related Articles |
| Ha B, Liao QM, Dix LP, et al.
Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies. [Journal Article]
HIV Clin Trials 2009 Mar-Apr; 10(2):65-75.
Abstract | Full Citation | Find Related Articles |
| Honda H, Gatanaga H, Matsumura J, et al.
Favourable use of non-boosted fosamprenavir in patients treated with warfarin. [Journal Article]
Int J STD AIDS 2009 Jun; 20(6):441.
Full Citation | Publisher Full Text | Find Related Articles |
| Rivas P, Morello J, Garrido C, et al.
Role of atazanavir in the treatment of HIV infection. [Journal Article]
Ther Clin Risk Manag 2009 Feb; 5(1):99-116.
Abstract | Full Citation | Find Related Articles |
| Landman R, Capitant C, Descamps D, et al.
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. [JOURNAL ARTICLE]
J Antimicrob Chemother 2009 May 6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Hill A, Sawyer W, Gazzard B
Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. [Journal Article]
HIV Clin Trials 2009 Jan-Feb; 10(1):1-12.
Abstract | Full Citation | Find Related Articles |
| Flamholc L, Gisslén M
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients. [Journal Article]
Ther Clin Risk Manag 2008 Dec; 4(6):1281-4.
Abstract | Full Citation | Find Related Articles |
   |
